Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

DDAVP stimulates prostacyclin production.

J J Belch, M Small, F McKenzie

    Thrombosis and Haemostasis
    |April 30, 1982
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    A platelet counting technique to study platelet aggregation in whole blood: application to pathologically low platelet counts.

    Platelets·2010
    Same author

    Effective inhibition of platelet aggregation in whole blood with a combination of dipyridamole and iloprost.

    Platelets·2010
    Same author

    Prevention of fibrinolytic shut-down after major surgery by intramuscular stanozolol.

    Thrombosis research·2010
    Same author

    The Scottish Heart and Arterial Risk Prevention (SHARP) survey of cardiovascular risk: regional differences.

    Scottish medical journal·2001
    Same author

    Results of a survey of cardiovascular risk factor prevalence amongst health care workers. The Executive Committee of SHARP--(Scottish Heart and Arterial Risk Prevention).

    Scottish medical journal·2000
    Same author

    A protocol for deep vein thrombosis.

    The Practitioner·2000

    Des-amino-D-arginine vasopressin (DDAVP) stimulates prostacyclin (PGI2) release, a potent anti-platelet agent. This mechanism may explain why DDAVP does not cause platelet activation in hemophiliacs.

    Area of Science:

    • Vascular biology
    • Endocrinology
    • Pharmacology

    Background:

    • Des-amino-D-arginine vasopressin (DDAVP) promotes factor VIII release.
    • Exogenous factor VIII infusion in hemophiliacs increases platelet activation.
    • DDAVP-induced factor VIII release does not elevate platelet activation, suggesting a counteracting mechanism.

    Purpose of the Study:

    • To investigate if DDAVP stimulates prostacyclin (PGI2) release.
    • To determine if PGI2 release by DDAVP counteracts factor VIII's pro-aggregating effect.
    • To explore the role of PGI2 in DDAVP's side effects.

    Main Methods:

    • In vitro study: Rabbit aortic rings incubated with DDAVP, measuring 6-oxo-PGF1 alpha (PGI2 metabolite) via radioimmunoassay.
    • In vivo study: Infusion of DDAVP into hemophiliacs, monitoring circulating 6-oxo-PGF1 alpha levels.

    Related Experiment Videos

  • Human study: Assessing DDAVP-induced facial flushing in normal subjects, with and without prior aspirin treatment.

    • Main Results:

    • DDAVP significantly increased 6-oxo-PGF1 alpha release from rabbit aortic rings in vitro.
    • Circulating 6-oxo-PGF1 alpha levels rose significantly in hemophiliacs post-DDAVP infusion.
    • Aspirin pretreatment abolished DDAVP-induced facial flushing in normal subjects, indicating PGI2 mediation.

    Conclusions:

    • DDAVP stimulates endothelial prostacyclin (PGI2) release.
    • PGI2 release likely counteracts potential platelet aggregation induced by DDAVP-mediated factor VIII increase.
    • Prostacyclin mediates the facial flushing side effect of DDAVP.